P-Glycoprotein-Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P-Glycoprotein-Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database.

MLA

Morishita, Hiroki, et al. “P-Glycoprotein-Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P-Glycoprotein-Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database.” Journal of Clinical Pharmacology, vol. 64, no. 1, Jan. 2024, pp. 118–24. EBSCOhost, https://doi.org/10.1002/jcph.2343.

APA

Morishita, H., Perera, L. M. B., Sunakawa, H., Kimura, S., Yoshida, H., & Ogihara, T. (2024). P-Glycoprotein-Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P-Glycoprotein-Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database. Journal of Clinical Pharmacology, 64(1), 118–124. https://doi.org/10.1002/jcph.2343

Chicago

Morishita, Hiroki, Liyanage Manosika Buddhini Perera, Hiroki Sunakawa, Satsuki Kimura, Hitoshi Yoshida, and Takuo Ogihara. 2024. “P-Glycoprotein-Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P-Glycoprotein-Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database.” Journal of Clinical Pharmacology 64 (1): 118–24. doi:10.1002/jcph.2343.